NS Pharma has shared exciting news of the launch of their expanded access program (EAP) for viltolarsen. This program will allow eligible patients with Duchenne Muscular Dystrophy amenable to exon 53 skipping to receive viltolarsen. This is a product under review of FDA and is being studied in NS Pharma’s global phase 3 confirmatory trial.
To view NS Pharma’s full press release regarding the EAP please click here. Also, for more information on EAP and inquires on participating in the EAP, physicians are to make requests on behalf of the patient, please email NS Pharma at email@example.com. Each case will be individually reviewed for eligibility.